Theolytics, a biotech focused on developing curative cancer therapies in the form of best-in-class oncolytic viruses, today announced the Board appointment of Carsten Reinhardt MD PhD.
Dr Reinhardt, currently Chief Development Officer and Managing Director of NASDAQ-listed Immatics Biotechnologies GmbH, is a visionary oncology and biotech expert, with extensive experience in translational development and early and late-stage clinical trial design, progressing multiple biological compounds from early preclinical development through first-in-man studies towards approvals in the US and Europe.
Dr Reinhardt said, “I very much look forward to working with Theolytics, a company that is revolutionizing the discovery and development of more effective and safer oncolytic virus therapies. The company’s revolutionary adenoviral-based selection platform enables a target product profile led, highly specific approach to drug discovery and may overcome many of the current limitations of immunooncology.”